Emerging drugs for bronchiectasis: an update

Bibliography

• Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR. Emerging drugs for bronchiectasis. Expert Opin Emerg Drugs 2012;17(3):361-78
   PubMed Web of Science ®Google Scholar
• King PT, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis. COPD 2005;2(1):27-34
   PubMedGoogle Scholar
• Chang AB, Masel JP, Boyce NC, et al. Non-CF bronchiectasis-clinical and HRCT evaluation. Pediatr Pulmonol 2003;35(6):477-83
   PubMed Web of Science ®Google Scholar
• Kapur N, Masters IB, Morris PS, et al. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012;47(1):68-75
   PubMed Web of Science ®Google Scholar
• King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100(4):2183-9
   PubMedGoogle Scholar
• Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4):1277-84
   PubMed Web of Science ®Google Scholar
• Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations: USA, 1993-2006. Chest 2010;138(4):944-9
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS ONE 2013;8(8):e71109
   PubMed Web of Science ®Google Scholar
• Chang AB, Grimwood K, Macguire G, et al. Management of bronchiectasis and chronic suppurative lung disease (CSLD) in Indigenous children and adults from rural and remote Australian communities. Med J Aust 2008;189(7):386-93
   PubMed Web of Science ®Google Scholar
• Silverman PM, Godwin JD. CT/bronchographic correlations in bronchiectasis. J Comput Assist Tomogr 1987;11(1):52-6
   PubMed Web of Science ®Google Scholar
• Hill LE, Ritchie G, Wightman AJ, et al. Comparison between conventional interrupted high-resolution CT and volume multidetector CT acquisition in the assessment of bronchiectasis. Br J Radiol 2010;83:67-70
   PubMed Web of Science ®Google Scholar
• Chang AB, Redding GJ, Everard ML. State of the Art - Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008;43(6):519-31
   PubMed Web of Science ®Google Scholar
• Kapur N, Masel JP, Watson D, et al. Bronchoarterial ratio on High Resolution CT scan of the chest in children without pulmonary pathology– Need to redefine bronchial dilatation. Chest 2011;139(6):1445-50
   PubMed Web of Science ®Google Scholar
• Santamaria F, Montella S, Pifferi M, et al. A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. Respiration 2009;77(2):160-5
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12(4):205-9
   Google Scholar
• Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010;104(7):981-5
   PubMed Web of Science ®Google Scholar
• Einsiedel L, Fernandes L, Spelman T, et al. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 2012;54(1):43-50
   PubMed Web of Science ®Google Scholar
• O’Grady KA, Torzillo PJ, Chang AB. Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. Med J Aust 2010;192(10):586-90
   PubMed Web of Science ®Google Scholar
• Twiss J, Metcalfe R, Edwards EA, Byrnes C. New Zealand national incidence of bronchiectasis “too high” for a developed country. Arch Dis Child 2005;90(7):737-40
   PubMed Web of Science ®Google Scholar
• Quint JK, Millett E, Hurst JR, et al. Time trends in incidence and prevalence of bronchiectasis in the UK. Thorax 2012;67:A138
   Web of Science ®Google Scholar
• Singleton RJ, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29(3):182-7
   PubMed Web of Science ®Google Scholar
• Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008;7(5):450-3
   PubMed Web of Science ®Google Scholar
• Chang AB. Editorial. Bronchiectasis: so much yet to learn and to do. Paediatr Respir Rev 2011;12:89-90
   PubMed Web of Science ®Google Scholar
• Available from: www.cff.org/AboutCF/[ Accessed 24 December 2014]
   Google Scholar
• Available from: www.aihw.gov.au/bronchiectasis [Accessed 4 December 2014]
   Google Scholar
• Joish VN, Spilsbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013;11(3):299-304
   PubMedGoogle Scholar
• Schraufnagel DE. editor. Breathing in America: Diseases, Progress, and Hope. American Thoracic Society; 2010
   Google Scholar
• Chang AB, Robertson CF, van Asperen PP, et al. Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation. Trials 2010;11(1):103
   PubMedGoogle Scholar
• Chang AB, Robertson CF, van Asperen PP, et al. A multi-centre study on chronic cough in children: burden and etiologies based on a standardized management pathway. Chest 2012;142:943-50
   PubMed Web of Science ®Google Scholar
• Kwak HJ, Moon JY, Choi YW, et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med 2010;222(4):237-42
   PubMed Web of Science ®Google Scholar
• Donnelly DE, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. Thorax 2007;62(1):80-4
   PubMed Web of Science ®Google Scholar
• Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high resolution computed tomography scans in severe asthma. Chest 2009;136(6):1521-8
   PubMed Web of Science ®Google Scholar
• O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55(8):635-42
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Donat SY, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140(5):1130-7
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, de la Rosa CD, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(8):823-31
   PubMed Web of Science ®Google Scholar
• Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140(3):626-33
   PubMed Web of Science ®Google Scholar
• Montes de OM, Halbert RJ, Lopez MV, et al. Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012;40(1):28-36
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Wedzicha JA. COPD exacerbations. 1: epidemiology. Thorax 2006;61(2):164-8
   PubMed Web of Science ®Google Scholar
• Guerra S, Sherrill DL, Venker C, et al. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009;64(10):894-900
   PubMed Web of Science ®Google Scholar
• Irwin RS. Complications of cough: accp evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):54S-58
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128(2):739-45
   PubMed Web of Science ®Google Scholar
• Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108(4):955-61
   PubMed Web of Science ®Google Scholar
• Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL. The course of childhood bronchiectasis: a case report and considerations of hospital use. Int J Circumpolar Health 1998;57(4):276-9
   PubMedGoogle Scholar
• Kapur N, Masters IB, Chang AB. Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009;103(11):1681-7
   PubMed Web of Science ®Google Scholar
• Cochrane GM. Chronic bronchial sepsis and progressive lung damage. BMJ 1985;290(6474):1026-7
   PubMed Web of Science ®Google Scholar
• Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006;35(1):58-65
   PubMed Web of Science ®Google Scholar
• Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. Eur J Respir Dis Suppl 1986;147(1):6-15
   PubMedGoogle Scholar
• Simons L, Simons J, Friedlander Y, McCallum J. Chronic bronchitis and risk of coronary heart disease. Lancet 1996;348(9038):1388-9
   PubMed Web of Science ®Google Scholar
• Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001;103(8):1064-70
   PubMed Web of Science ®Google Scholar
• Hill SL, Burnett D, Hewetson KA, Stockley RA. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med 1988;66(250):163-73
   PubMedGoogle Scholar
• Erdem E, Ersu R, Karadag B, et al. Effect of night symptoms and disease severity on subjective sleep quality in children with non-cystic-fibrosis bronchiectasis. Pediatr Pulmonol 2011;46(9):919-26
   PubMed Web of Science ®Google Scholar
• Prys-Picard CO, Niven R. Urinary incontinence in patients with bronchiectasis. Eur Respir J 2006;27(4):866-7
   PubMed Web of Science ®Google Scholar
• O’Leary CJ, Wilson CB, Hansell DM, et al. Relationship between psychological well-being and lung health status in patients with bronchiectasis. Respir Med 2002;96(9):686-92
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9
   PubMed Web of Science ®Google Scholar
• Steinfort DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 2008;102(4):574-8
   PubMed Web of Science ®Google Scholar
• Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J 1997;10(12):2784-7
   PubMed Web of Science ®Google Scholar
• Mandal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33
   PubMed Web of Science ®Google Scholar
• Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 2012;141(4):1018-24
   PubMed Web of Science ®Google Scholar
• Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-CF bronchiectasis - what influences lung function stability? Chest 2010;138(1):158-64
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189(5):576-85
   PubMed Web of Science ®Google Scholar
• Gao Y, Guan W, Xu G, et al. The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: A prospective study. Chest 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kapur N, Mackay IM, Sloots TP, et al. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch Dis Child 2014;99(8):749-53
   PubMed Web of Science ®Google Scholar
• Redding GJ, Singleton RJ, Valery PC, et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Chest 2014;146(3):762-74
   PubMed Web of Science ®Google Scholar
• Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014;11(4):496-503
   PubMedGoogle Scholar
• Dogru D, Nik-Ain A, Kiper N, et al. Bronchiectasis: the consequence of late diagnosis in chronic respiratory symptoms. J Trop Pediatr 2005;51(6):362-5
   PubMed Web of Science ®Google Scholar
• Haidopoulou K, Calder A, Jones A, et al. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009;44(7):669-75
   PubMed Web of Science ®Google Scholar
• Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33(2):312-18
   PubMed Web of Science ®Google Scholar
• Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009;64(3):246-51
   PubMed Web of Science ®Google Scholar
• Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997;10(10):2376-9
   PubMed Web of Science ®Google Scholar
• Chang AB, Byrnes CA, Everard ML. Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis. Paediatr Respir Rev 2011;12(2):97-103
   PubMed Web of Science ®Google Scholar
• Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003;47(3):215-20
   PubMed Web of Science ®Google Scholar
• Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008;14(6):595-9
   PubMed Web of Science ®Google Scholar
• Gharagozlou M, Ebrahimi FA, Farhoudi A, et al. Pulmonary complications in primary hypogammaglobulinemia: a survey by high resolution CT scan. Monaldi Arch Chest Dis 2006;65(2):69-74
   PubMedGoogle Scholar
• Karadag B, Karakoc F, Ersu R, et al. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005;72(3):233-8
   PubMed Web of Science ®Google Scholar
• Babayigit A, Olmez D, Uzuner N, et al. A neglected problem of developing countries: noncystic fibrosis bronchiectasis. Ann Thorac Med 2009;4(1):21-4
   PubMed Web of Science ®Google Scholar
• Grimwood K, Bell SC, Chang AB. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev Anti Infect Ther 2014;12(10):1277-96
   PubMed Web of Science ®Google Scholar
• Sidhu MK, Mandal P, Hill AT. Developing drug therapies in bronchiectasis. Expert Opin Investig Drugs 2015;24(2):169-81
   PubMed Web of Science ®Google Scholar
• Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian Indigenous children with bronchiectasis. J Pediatr 2010;157(6):1001-5
   PubMed Web of Science ®Google Scholar
• Van Eldere J, Slack MP, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis 2014;14(12):1281-92
   PubMed Web of Science ®Google Scholar
• Chang AB, Bell SC, Byrnes CA, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: thoracic Society of Australia and New Zealand and Australian Lung Foundation Position Statement. Med J Aust 2010;193(6):356-65
   PubMed Web of Science ®Google Scholar
• Kapur N, Grimwood K, Masters IB, et al. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012;47(3):300-7
   PubMed Web of Science ®Google Scholar
• Goyal V, Grimwood K, Chang AB. Bronchiectasis: the arrival of better evidence. Lancet Respir Med 2014;2:12-13
   PubMed Web of Science ®Google Scholar
• Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986;41(7):559-65
   PubMed Web of Science ®Google Scholar
• Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155(6):2024-9
   PubMed Web of Science ®Google Scholar
• Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60
   PubMed Web of Science ®Google Scholar
• Ip M, Shum D, Lauder I, et al. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993;87(6):449-54
   PubMed Web of Science ®Google Scholar
• Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990;76(280):799-816
   PubMedGoogle Scholar
• Bahous J, Cartier A, Pneau L, et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984;20(4):375-80
   PubMedGoogle Scholar
• Ip M, Lam WK, So SY, et al. Analysis of factors associated with bronchial hyperactivity to methacholine in bronchiectasis. Lung 1991;169(1):43-51
   PubMed Web of Science ®Google Scholar
• Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61(5):414-18
   PubMed Web of Science ®Google Scholar
• Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009(1):CD000996
   Google Scholar
• Hernando R, Drobnic ME, Cruz MJ, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm 2012;34(4):644-50
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
   PubMed Web of Science ®Google Scholar
• Guran T, Ersu R, Karadag B, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008;33(6):603-11
   PubMed Web of Science ®Google Scholar
• Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2003(1):CD003572
   Google Scholar
• Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev 2001(4):CD002155
   Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141(2):461-8
   PubMed Web of Science ®Google Scholar
• Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014(6):CD010327
   Google Scholar
• Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
   PubMed Web of Science ®Google Scholar
• Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105(12):1831-5
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005;10(1):46-56
   PubMed Web of Science ®Google Scholar
• Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106(5):661-7
   PubMed Web of Science ®Google Scholar
• Crockett AJ, Cranston JM, Latimer KM, Alpers JH. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2001(1):CD001289
   Google Scholar
• Jones AP, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003(3):CD001127
   Google Scholar
• O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113(5):1329-34
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Coletti O, Costi S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther 2007;29(9):2001-9
   PubMed Web of Science ®Google Scholar
• Fuschillo S, De FA, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31(2):396-406
   PubMed Web of Science ®Google Scholar
• Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(5):1086-92
   PubMed Web of Science ®Google Scholar
• Patterson JE, Hewitt O, Kent L, et al. Acapella versus ’usual airway clearance’ during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis 2007;4(2):67-74
   PubMedGoogle Scholar
• Llewellyn-Jones CG, Johnson MM, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
   PubMed Web of Science ®Google Scholar
• Kapur N, Chang A. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(4):CD006427
   Google Scholar
• Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010(4):CD007525
   Google Scholar
• Katsura H, Ogata M, Kida K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary oxygen therapy. Monaldi Arch Chest Dis 2001;56(3):195-201
   PubMedGoogle Scholar
• Failla ML. Trace elements and host defense: recent advances and continuing challenges. J Nutr 2003;133(5 Suppl 1):1443S-7S
   PubMed Web of Science ®Google Scholar
• Grant CC. Pneumonia in children: becoming harder to ignore. N Z Med J 1999;112(1095):345-7
   PubMedGoogle Scholar
• Black RE. Therapeutic and preventive effects of zinc on serious childhood infectious diseases in developing countries. Am J Clin Nutr 1998;68(2 Suppl):476S-9S
   PubMed Web of Science ®Google Scholar
• Dudley L, Hussey G, Huskissen J, Kessow G. Vitamin A status, other risk factors and acute respiratory infection morbidity in children. S Afr Med J 1997;87(1):65-70
   PubMed Web of Science ®Google Scholar
• Hovden AO, Cox RJ, Haaheim LR. Influenza: the virus and prophylaxis with inactivated influenza vaccine in “at risk” groups, including COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2(3):229-40
   PubMedGoogle Scholar
• Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(3):CD006218
   Google Scholar
• Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009(2):CD006316
   Google Scholar
• Li JS, Peat JK, Xuan W, Berry G. Meta-analysis on the association between environmental tobacco smoke (ETS) exposure and the prevalence of lower respiratory tract infection in early childhood. Pediatr Pulmonol 1999;27(1):5-13
   PubMed Web of Science ®Google Scholar
• Acharya D, Prasanna KS, Nair S, Rao RS. Acute respiratory infections in children: a community based longitudinal study in south India. Indian J Public Health 2003;47(1):7-13
   PubMedGoogle Scholar
• Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011(3):CD005353
   Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011(2):CD006103
   PubMed Web of Science ®Google Scholar
• Jeffry Modell Centers Network. Economic Impact Study: comparing Undiagnosed and Diagnosed Patients with Primary Immunodeficiencies. 2012. Available from: http://www info4pi org/scientific_publications/pdf/Economic_Impact_110107 pdf [Accessed 25 March 2012]
   Google Scholar
• Lavery KA, O’Neill B, Parker M, et al. Expert patient self-management program versus usual care in bronchiectasis: a randomized controlled trial. Arch Phys Med Rehabil 2011;92(8):1194-201
   PubMed Web of Science ®Google Scholar
• Newcombe PA, Sheffield JK, Juniper EF, et al. Development of a parent-proxy quality-of-life chronic cough-specific questionnaire: clinical impact vs psychometric evaluations. Chest 2008;133(2):386-95
   PubMed Web of Science ®Google Scholar
• Milne RJ, Hockey H, Rea H. Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis. Value Health 2014;17(4):320-7
   PubMed Web of Science ®Google Scholar
• Doeschl-Wilson AB, Davidson R, Conington J, et al. Implications of host genetic variation on the risk and prevalence of infectious diseases transmitted through the environment. Genetics 2011;188(3):683-93
   PubMed Web of Science ®Google Scholar
• Chang AB, Yerkovich ST, Gibson PG, et al. Pulmonary innate immunity in children with protracted bacterial bronchitis. J Pediatr 2012;161:621-5
   PubMed Web of Science ®Google Scholar
• Wong SM, Akerley BJ. Genome-scale approaches to identify genes essential for Haemophilus influenzae pathogenesis. Front Cell Infect Microbiol 2012;2:23
   Google Scholar
• Pizzutto SJ, Yerkovich ST, Upham JW, et al. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae. PLoS ONE 2014;9(8):e104236
   PubMed Web of Science ®Google Scholar
• Tunney MM, Einarsson GG, Wei L, et al. The lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187:1118-26
   PubMed Web of Science ®Google Scholar
• Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731-7
   PubMed Web of Science ®Google Scholar
• van der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc 2014;11(7):1039-48
   PubMedGoogle Scholar
• Chang AB, Marsh RL, Upham JW, CRE extended group. Towards making inroads in reducing. the disparity of lung health in Australian Indigenous and New Zealand Mâori children. Front Pediatr 2015;3:9
   PubMed Web of Science ®Google Scholar
• Kapur N, Karadag B. Differences and similarities in non-CF BE between developing and affluent countries. Paediatr Respir Rev 2011;12(2):91-6
   PubMed Web of Science ®Google Scholar
• King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009;6(2):130-6
   PubMedGoogle Scholar
• Stockley RA, Bayley D, Hill SL, et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001;56(5):366-72
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Vandooren J, Moelants EA, et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology 2014;19(2):203-10
   PubMed Web of Science ®Google Scholar
• Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. A position statement. Med J Aust 2002;177(4):200-4
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-i58
   PubMed Web of Science ®Google Scholar
• Chang AB, Bell SC, Torzillo PJ, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: Thoracic Society of Australia
   Google Scholar
• Chang AB, Bilton D. Non-cystic fibrosis bronchiectasis exacerbations. Thorax 2008;63(3):269-76
   PubMed Web of Science ®Google Scholar
• Quittner AL, O’Donnell AE, Salathe MA, et al. Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015;70(1):12-20
   PubMed Web of Science ®Google Scholar
• de Camargo AA, Amaral TS, Rached SZ, et al. Incremental shuttle walking test: a reproducible and valid test to evaluate exercise tolerance in adults with noncystic fibrosis bronchiectasis. Arch Phys Med Rehabil 2014;95(5):892-9
   PubMed Web of Science ®Google Scholar
• Murray MP, Turnbull K, Macquarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(1):125-31
   PubMed Web of Science ®Google Scholar
• Murray MP, Pentland JL, Turnbull K, et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(2):361-4
   PubMed Web of Science ®Google Scholar
• Wilson R, Dowling RB, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996;9(7):1523-30
   PubMed Web of Science ®Google Scholar
• Slauson DO, Hahn FF. Criteria for development of animal models of diseases of the respiratory system: the comparative approach in respiratory disease model development. Am J Pathol 1980;101(3 Suppl):S103-22
   PubMedGoogle Scholar
• McNeil C, Macgregor AR, Alexander WA. Studies of pneumonia in childhood: IV. Bronchiectasis and fibrosis of the lung. Arch Dis Child 1929;4:170-89
   PubMedGoogle Scholar
• Finke W. Prospects for prevention of chronic bronchitis and bronchiectasis; rational management of bronchopulmonary infections by penicillin aerosol therapy. J Pediatr 1948;33(1):29-42
   PubMed Web of Science ®Google Scholar
• Field CE. Bronchiectasis in childhood; III. Prophylaxis, treatment and progress with a follow-up study of 202 cases of established bronchiectasis. Pediatrics 1949;4(3):355-72
   PubMed Web of Science ®Google Scholar
• Croxatto OC, Lanari A. Pathogenesis of bronchiectasis; experimental study and anatomic findings. J Thorac Surg 1954;27(5):514-28
   PubMedGoogle Scholar
• Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13(1):21
   PubMedGoogle Scholar
• Stockley RA. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax 1998;53(1):58-62
   PubMed Web of Science ®Google Scholar
• Delarue JA, Abelanet RM. Pathogenesis of bronchiectasis; an experimental study. Dis Chest 1959;35(4):394-408
   PubMedGoogle Scholar
• Beasley V, Joshi PV, Singanayagam A, et al. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:555-69
   PubMed Web of Science ®Google Scholar
• Chan TB, Arm JP, Anderson J, Eiser NM. Pulmonary epithelial permeability in bronchiectasis. Br J Dis Chest 1988;82(1):56-63
   PubMedGoogle Scholar
• Marsh RL, Thornton RB, Smith-Vaughan HC, et al. Identification of biofilm in bronchoalveolar lavage from children with bronchiectasis without Pseudomonas aeruginosa infection. Pediatr Pulmonol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Zawrotniak M, Rapala-Kozik M. Neutrophil extracellular traps (NETs) - formation and implications. Acta Biochim Pol 2013;60(3):277-84
   PubMed Web of Science ®Google Scholar
• Kapur N, Grimwood K, Masters IB, et al. Bronchoalveolar lavage fluid microbiology and airway cellularity in children newly diagnosed with bronchiectasis. Respirology 2010;15(Suppl 2):A29
   Google Scholar
• Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007;62(3):211-18
   PubMed Web of Science ®Google Scholar
• Pizzutto SJ, Grimwood K, Bauert P, et al. Bronchoscopy contributes to the clinical management of Indigenous children newly doagnosed with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2013;48(1):67-73
   PubMed Web of Science ®Google Scholar
• Ayars GH, Altman LC, Gleich GJ, et al. Eosinophil- and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol 1985;76(4):595-604
   PubMed Web of Science ®Google Scholar
• Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008;134(3):606-12
   PubMed Web of Science ®Google Scholar
• Meijer M, Rijkers GT, van Overveld FJ. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert Rev Clin Immunol 2013;9(11):1055-68
   PubMed Web of Science ®Google Scholar
• Filep JG. Resolution of inflammation: leukocytes and molecular pathways as potential therapeutic targets. Front Immunol 2013;4:256
   Google Scholar
• Sabroe I, Whyte MK. Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease. Biochem Soc Trans 2007;35(Pt 6):1492-5
   PubMedGoogle Scholar
• Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006;129(6):1673-82
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in COPD. Am J Respir Crit Care Med 2008;178(2):139-48
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Scicchitano R, et al. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003;81(4):289-96
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Ahern J, et al. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007;37(6):748-55
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005;25(3):447-54
   PubMed Web of Science ®Google Scholar
• Voglis S, Quinn K, Tullis E, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009;180(2):159-66
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Brozyna S, et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006;28(3):486-95
   PubMed Web of Science ®Google Scholar
• El KD, Filep JG. Targeting neutrophil apoptosis for enhancing the resolution of inflammation. Cells 2013;2(2):330-48
   Google Scholar
• Kistemaker LE, van Os RP, Dethmers-Ausema A, et al. Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol 2015;308(1):96-L103
   PubMed Web of Science ®Google Scholar
• Gilley SK, Stenbit AE, Pasek RC, et al. Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways. Am J Physiol Lung Cell Mol Physiol 2014;306(2):L162-9
   PubMed Web of Science ®Google Scholar
• Cheng KK. The experimental production of bronchiectasis in rats. J Pathol Bacteriol 1954;67(1):89-98
   PubMedGoogle Scholar
• Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52(9):1176-93
   PubMed Web of Science ®Google Scholar
• King PT, Ngui J, Gunawardena D, et al. Systemic humoral immunity to non-typeable Haemophilus influenzae. Clin Exp Immunol 2008;153(3):376-84
   PubMed Web of Science ®Google Scholar
• King PT, Lim S, Pick A, et al. Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131(5):1314-21
   PubMed Web of Science ®Google Scholar
• Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008;102(10):1494-6
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159(6):1843-8
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med 2010;104(3):371-7
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
   PubMed Web of Science ®Google Scholar
• Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014;69(12):1073-9
   PubMed Web of Science ®Google Scholar
• Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013;12(4):367-76
   PubMed Web of Science ®Google Scholar
• Cataldi M, Sblendorio V, Leo A, Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther 2014;28(2):98-108
   PubMed Web of Science ®Google Scholar
• Pinner NA, Hamilton LA, Hughes A. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 2012;34(1):56-66
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Beghé B, Yasothan U, Kirkpatrick P. Roflumilast. Nat Rev Drug Discov 2010;9(10):761-2
   PubMed Web of Science ®Google Scholar
• Nicholls DJ, Tomkinson NP, Wiley KE, et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 2008;74(5):1193-202
   PubMed Web of Science ®Google Scholar
• Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121(1):55-68
   PubMed Web of Science ®Google Scholar
• Pavord I, De Soyza A, Elborn JS, et al. Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. Eur Respir J 2013;42(Suppl 57):P1593
   Google Scholar
• Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99(13):8921-6
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
   PubMed Web of Science ®Google Scholar
• Chiu AG, Chen B, Palmer JN, et al. Safety evaluation of sinus surfactant solution on respiratory cilia function. Int Forum Allergy Rhinol 2011;1(4):280-3
   Google Scholar
• Matera MG, Calzetta L, Segreti A, Cazzola M. Emerging drugs for chronic obstructive pulmonary disease. Expert Opin Emerg Drugs 2012;17(1):61-82
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010;19(5):330-8
   PubMed Web of Science ®Google Scholar
• Ip M, Lam WK, Chan JC, Liong E. Systemic effects of inflammation in bronchiectasis. Respir Med 1991;85(6):521-5
   PubMed Web of Science ®Google Scholar
• Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014;2(6):455-63
   PubMed Web of Science ®Google Scholar
• Mutak S. Azalides from azithromycin to new azalide derivatives. J Antibiot (Tokyo) 2007;60(2):85-122
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Papanas N, Kioumis I, et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68(5):479-503
   PubMed Web of Science ®Google Scholar
• Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010;36(3):646-54
   PubMed Web of Science ®Google Scholar
• Starner TD, Shrout JD, Parsek MR, et al. subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob Agents Chemother 2008;52(1):137-45
   PubMed Web of Science ®Google Scholar
• Available from: www uspto gov/web/patents/patog/week51/OG/html/1373-3/US08080529-20111220 html 2012
   Google Scholar
• Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev 2006(4):CD001958
   Google Scholar
• Tandon MK, Phillips M, Waterer G, et al. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 2010;137(4):805-11
   PubMed Web of Science ®Google Scholar
• Pizzutto SJ, Yerkovich ST, Upham JW, et al. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. Vaccine 2015;33(2):321-6
   PubMed Web of Science ®Google Scholar
• De BF, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidiscip Respir Med 2013;8(1):33
   Google Scholar
• Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther 2012;25(1):62-8
   PubMed Web of Science ®Google Scholar
• King PT, Hutchinson P, Holmes PW, et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol 2006;144(3):440-6
   PubMed Web of Science ®Google Scholar
• King P, Bnett-Wood V, Hutchinson P, et al. Bactericidal activity of neutrophils with reduced oxidative burst from adults with bronchiectasis. APMIS 2009;117(2):133-9
   PubMed Web of Science ®Google Scholar
• Ruchaud-Sparagano MH, Gertig H, Hester KL, et al. Effect of granulocyte-macrophage colony-stimulating factor on neutrophil function in idiopathic bronchiectasis. Respirology 2013;18(8):1230-5
   PubMed Web of Science ®Google Scholar
• Chang AB. Specialty grand challenge – pediatric pulmonology. Front Pediatr 2013;1:14
   Google Scholar
• Campbell F, Conti G, Heckman JJ, et al. Early childhood investments substantially boost adult health. Science 2014;343(6178):1478-85
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. Am J Roentgenol 2003;180(2):513-18
   PubMed Web of Science ®Google Scholar